Axsome Therapeutics (AXSM) Other Non-Current Assets (2015 - 2022)
Axsome Therapeutics recorded quarterly Other Non-Current Assets of $507464.0 in Q2 2022, up 57.15% quarter-over-quarter from $322910.0 in Q1 2022, and up 59.89% year-over-year from $317375.0 in Q2 2021.
Axsome Therapeutics' Other Non-Current Assets history runs 8 years deep, the most recent figure standing at $507464.0 for Q2 2022.
- In Q2 2022, Other Non-Current Assets rose 59.89% year-over-year to $507464.0; the TTM figure through Jun 2022 stood at $507464.0 (up 59.89% YoY), while the FY2021 annual figure was $322910.0, up 1.74% from the prior year.
- Other Non-Current Assets came in at $507464.0 for Q2 2022 at Axsome Therapeutics, up from $322910.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $507464.0 in Q2 2022 to a low of $101516.0 in Q1 2019.
- A 5-year average of $226134.4 and a median of $168969.0 in 2019 frame the typical range for Other Non-Current Assets.
- Across the five-year window, Other Non-Current Assets tumbled 40.23% in 2018 and jumped 126.9% in 2020, its largest moves.
- Axsome Therapeutics' Other Non-Current Assets stood at $112345.0 in 2018, then increased by 24.5% to $139875.0 in 2019, then surged by 126.9% to $317375.0 in 2020, then rose by 1.74% to $322910.0 in 2021, then jumped by 57.15% to $507464.0 in 2022.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $507464.0, $322910.0, and $322910.0 for Q2 2022, Q1 2022, and Q4 2021 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Axsome Therapeutics | 11.82 Bn | 11.51 Bn | 176.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 507,464.00 |
| Mar 31, 2022 | 322,910.00 |
| Dec 31, 2021 | 322,910.00 |
| Sep 30, 2021 | 322,910.00 |
| Jun 30, 2021 | 317,375.00 |
| Mar 31, 2021 | 317,375.00 |
| Dec 31, 2020 | 317,375.00 |
| Sep 30, 2020 | 317,375.00 |
| Jun 30, 2020 | 139,875.00 |
| Mar 31, 2020 | 143,575.00 |
| Dec 31, 2019 | 139,875.00 |
| Sep 30, 2019 | 168,969.00 |
| Jun 30, 2019 | 168,969.00 |
| Mar 31, 2019 | 101,516.00 |
| Dec 31, 2018 | 112,345.00 |
| Sep 30, 2018 | 117,356.00 |
| Jun 30, 2018 | 117,356.00 |
| Mar 31, 2018 | 114,889.00 |
| Dec 31, 2017 | 187,952.00 |
| Sep 30, 2017 | 119,291.00 |
| Jun 30, 2017 | 119,291.00 |
| Mar 31, 2017 | 119,291.00 |
| Dec 31, 2016 | 112,821.00 |
| Sep 30, 2016 | 59,125.00 |
| Jun 30, 2016 | 57,500.00 |
| Mar 31, 2016 | 57,500.00 |
| Dec 31, 2015 | 26,625.00 |